Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients (ICM)
This study has been terminated.
( We could not recruit patients willing to be enrolled )
Study NCT00529633   Information provided by University of California, Davis

First Received on September 12, 2007.   Last Updated on September 25, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypoalbuminemia
Additional conditions recognized in this trial
Systemic Inflammatory Response Syndrome
More general conditions related to this trial
Blood Protein Disorders
Hematologic Diseases
Hypoproteinemia
Inflammation
Pathologic Processes
Shock
Interventions listed in this trial
thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of California, Davis
Beth Israel Medical Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services